Patients Why patient safety doesn't end at approval Once a treatment becomes available to the public, protecting patient safety remains a priority throughout its time on the market.
Market Access Keeping local affiliates on track with pharmacovigilance Local affiliates can be overwhelmed by the often-competing demands of global companies and local health authorities.
News Rhapsido is first drug cleared for chronic hives disorder SD Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication that causes chronic hives.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
